Adicet soars on early responses to gamma delta CAR-T therapy Investors punish Aeglea for missed rare disease secondaries, sending stock spiraling despite primary endpoint success 'We're getting there': LGBTQ+ progress in biotech lingers in the 'diagnose' stage Biohaven pain spray aces test as C-suite shake-up sees incoming CFO, chief in chairman role Gilead-partnered Goldfinch Bio snags 13-year Ardelyx vet to lead scientific operations of kidney assets BenevolentAI to take drug discovery tech public in Europe's largest SPAC deal, valued at €1.5B AstraZeneca weighs spinning out COVID-19 products into separate company: Bloomberg Black patient inclusion in clinical trials improves, but Asian, Latino and other groups 'significantly' underrepresented Improving CAR-T cell therapies for cancer by targeting a protein 'brake' Featured Story | By Nick Paul Taylor Adicet Bio has laid down a marker for the nascent gamma delta CAR-T cell therapy space, reporting its off-the-shelf candidate ADI-001 triggered responses in a small clinical trial of B-cell non-Hodgkin lymphoma patients. Shares in Adicet jumped 45% to above $14 in premarket trading. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Aeglea BioTherapeutics found itself in an unusual position going into the readout from its pivotal rare disease clinical trial. With Aeglea expected to meet its primary endpoint, investors were focused on whether it could show clinical improvement of a secondary measure—and were swift to punish the stock when it fell short of expectations. read more By Kyle LaHucik The biotech industry is "getting there" in terms of advancing LGBTQ+ inclusion, but it's an effort that remains in the early innings. Fierce Biotech spoke with more than 20 LGBTQ+ leaders in biopharma to learn where the industry stands on incorporating the LGBTQ+ community into its diversity and inclusion work. read more By Ben Adams Biohaven is eyeing filing for approval early next year for its experimental pain spray after new data showed it hit its primary endpoints in a phase 3 test. read more By Kyle LaHucik Goldfinch Bio hopes a 13-year Ardelyx veteran can help it advance mid-stage and early-phase kidney disease drugs. Jeff Jacobs joins the Gilead-partnered biotech after helping Ardelyx get its own kidney disease drug approved in autumn 2019, but the company has been mired by a recent rejection for the same drug and mass layoffs. read more By Andrea Park In the course of its combination with special purpose acquisition company Odyssey—which went public in a 300 million euro IPO of its own earlier this year—BenevolentAI will rake in up to 390 million euro in net proceeds. read more By Angus Liu AstraZeneca recently bundled its COVID-19 vaccine and antibody treatment into a separate division. But there’s a chance that the new unit might not stay with the British drugmaker for long, as the firm is reportedly considering various options including a potential spinoff, Bloomberg reported. read more By Kyle LaHucik Clinical trials had more Black patients in the past decade, but studies of investigational drugs continued to underrepresent patients from Asian, Latino, Hispanic and Native American backgrounds. Clinical development data provider Phesi analyzed trials that began in the past decade, sifting through data on 1.3 million U.S. patients. read more By Angus Liu CAR-T cells to treat cancer have precious little time to proliferate in the body, which often limits their anti-tumor efficacy. A team at the Curie Institute pinpointed the protein SOCS1 as an inhibitor of CAR-T expansion and survival and suggested it could be targeted to improve T-cell therapies. read more |
| Webinar: Addressing challenges across the AAV manufacturing workflow Watch this webinar to learn how to scale-up your viral production protocols faster, through upstream and downstream solutions, without compromising quality or safety. Watch now! |
Resources Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored By: BBK Worldwide Create more inclusive clinical trials, enroll them faster, and keep participants engaged longer with the latest Study Voices survey results and insights. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA Fierce Business Development and Licensing Summit March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2022 | Location TBD Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event | 